Company intelligence / Profile preview

BioSpecifics Technologies

Ownership: Private
Employees: ~15
Development stage: Other

Overview

BioSpecifics developed and commercialized injectable collagenase clostridium histolyticum (marketed as XIAFLEX in the US and Xiapex in Europe) for Dupuytren’s contracture and Peyronie’s disease. The company also advanced CCH into late-stage development for cellulite ("Qwo") and explored additional indications such as adhesive capsulitis and various benign tumors. Positive clinical results were reported across multiple indications prior to acquisition by Endo International.

Therapeutic areas: Metabolic DisordersDermatologyMen's HealthOncologyRheumatologyWomen's Health
Modalities: Recombinant proteaseEnzyme (collagenase)Biologic
Industry: Biotech

Partnerships

Endo International plc (global commercialization/development partner)Swedish Orphan Biovitrum AB ("Sobi", European partner)Auxilium Pharmaceuticals(former US partner before Endo acquired Auxilium)

Beyond the preview

Go deeper on BioSpecifics Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioSpecifics Technologies.

Explore the full profile